Valion Bio Inc (VBIO) - Total Liabilities
Based on the latest financial reports, Valion Bio Inc (VBIO) has total liabilities worth $14.81 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Valion Bio Inc annual equity growth to track the company's year-over-year net asset growth rate.
Valion Bio Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Valion Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See Valion Bio Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Valion Bio Inc Competitors by Total Liabilities
The table below lists competitors of Valion Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avation PLC
LSE:AVAP
|
UK | GBX762.44 Million |
|
Lucibel
PA:ALUCI
|
France | €6.99 Million |
|
Baumart Holdings Ltd
AU:BMH
|
Australia | AU$1.10 Million |
|
Global Energy Metals Corp
V:GEMC
|
Canada | CA$619.86K |
|
Ampli SA w upadlosci ukladowej
WAR:APL
|
Poland | zł2.19 Million |
|
ARCTIC BLUE BEVERAGES AB
F:U5L
|
Germany | €22.19 Million |
|
Visionary Education Technology Holdings Group Inc.
NASDAQ:GV
|
USA | $58.43 Million |
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
Israel | ILA5.57 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Valion Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VBIO company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Valion Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Valion Bio Inc (2017–2025)
The table below shows the annual total liabilities of Valion Bio Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.81 Million | +5344.85% |
| 2024-12-31 | $272.00K | -82.75% |
| 2023-12-31 | $1.58 Million | -29.76% |
| 2022-12-31 | $2.25 Million | +6613.52% |
| 2020-12-31 | $33.44K | -97.40% |
| 2019-12-31 | $1.28 Million | +263.45% |
| 2017-12-31 | $353.52K | -- |
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more